KYMR
Kymera Therapeutics Inc
107.40$
-2.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 19.0% | 1.8% | 14.6% | 7.4% | 53.5% | 26.7% | 9.3% | 18.2% | 2,680.7% | -2,663.6% | 5.9% | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 81.8% | -2,580.7% | 2,763.6% | 100.0% | 100.0% | 102.0% | |
| 1,017.7% | 110.6% | 474.6% | 230.8% | 1,614.8% | 971.3% | 363.1% | 683.1% | 2,680.7% | 2,932.3% | 285.6% | 183.8% | 357.8% | |
| 298.6% | 29.7% | 139.7% | 67.7% | 413.1% | 220.9% | 73.6% | 153.8% | 627.2% | 592.6% | 59.2% | 32.5% | 72.2% | |
| 1,316.3% | 140.3% | 662.2% | 298.5% | 2,027.9% | 1,192.2% | 436.8% | 818.7% | 766.7% | 6,186.5% | 344.9% | 216.3% | 435.5% | |
| -1,216.3% | -40.3% | -562.2% | -198.5% | -1,927.9% | -1,092.2% | -336.8% | -736.8% | -3,347.4% | -3,422.9% | -244.9% | -116.3% | -333.5% | |
| 0.9% | 0.1% | 0.7% | 0.2% | 1.6% | 0.8% | 0.3% | 0.9% | 3.5% | 2.4% | 0.2% | 0.1% | 0.3% | |
| -1,118.2% | -30.0% | -472.0% | -164.0% | -1,670.3% | -956.9% | -296.7% | -667.6% | -2,973.0% | -3,050.8% | -201.5% | -94.2% | -285.6% | |
| -18.9% | 10.4% | 0.4% | – | -53.5% | – | – | – | – | – | – | – | – | |
| -1,118.2% | -30.0% | -472.0% | -164.0% | -1,670.3% | -956.9% | -296.7% | -667.6% | -2,973.0% | -3,043.0% | -201.5% | -94.2% | -285.4% | |
| -1,098.3% | -28.1% | -457.1% | -156.2% | -1,615.6% | -929.2% | -287.2% | -648.5% | -2,870.0% | -2,977.3% | -195.4% | -94.0% | -278.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.